Editas Medicine Announces Second Quarter 2022 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Editas Medicine (EDIT) Tops Q2 EPS by 3c
August 3, 2022 6:43 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.78), $0.03 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.36 million versus the consensus estimate of $4.29 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More